Research Topics
| B StroberSummaryCountry: USA Publications
| Collaborators
|
Detail Information
Publications
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled studyBruce E Strober
Department of Dermatology, New York University Medical Center, 550 First Ave, TCH 158, New York, NY 10016, USA
Arch Dermatol 145:1262-6. 2009..To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA)...
Alefacept for the treatment of psoriasis and other dermatologic diseasesBruce E Strober
Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
Dermatol Ther 20:270-6. 2007..Some patients who achieve PASI 75 also experience long-term remissions from psoriasis. The drug is well-tolerated and adverse events are rare. Off-label use of the drug is growing and may be formally explored in the future...
Conventional systemic agents for psoriasis. A systematic reviewBruce E Strober
New York University School of Medicine, New York, New York 10016, USA
J Rheumatol 33:1442-6. 2006..This is a systematic, evidence-based review of the literature evaluating both the efficacy and safety of the medications cyclosporine, methotrexate, acitretin, hydroxyurea, and 6-thioguanine. Treatment recommendations are made...
Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritisB Strober
Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA
Br J Dermatol 159:322-30. 2008..C-reactive protein (CRP), an inflammation biomarker, indicates cardiovascular risk and is elevated in psoriasis. The effect of etanercept on CRP in psoriasis has not been previously examined...
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilastA B Gottlieb
Department of Dermatology, Tufts University, Boston, MA 02111 1533, USA
Curr Med Res Opin 24:1529-38. 2008..To evaluate the clinical and biological activity of apremilast in patients with severe plaque-type psoriasis...
Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATEEllen H Frankel
Clinical Partners LLC, Cranston, Rhode Island 02910, USA
Cutis 79:322-6. 2007..We present data on patient-reported outcomes (PROs) from EDUCATE, which demonstrate that subjects with PsA achieved clinically meaningful improvements in both skin- and joint-related PROs after 24 weeks of treatment...
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter
Division of Dermatology, Baylor Research Institute, University of Texas Southwestern Medical School, 3900 Junius St, 125, Dallas, TX 75246 1613, USA
J Am Acad Dermatol 58:106-15. 2008..Adalimumab is a fully human monoclonal antibody that binds tumor necrosis factor, a key proinflammatory cytokine involved in the pathogenesis of psoriasis...
Tinea versicolor associated with etanercept therapyMarla S Levy
J Am Acad Dermatol 58:S99-100. 2008
Off-label dermatologic uses of anti-TNF-a therapiesAndrew F Alexis
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, NY, USA
J Cutan Med Surg 9:296-302. 2005..CONCLUSIONS: A growing number of published reports suggest that anti-TNF-a therapies may be effective in the treatment of numerous inflammatory skin diseases outside their currently approved indications...
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyAlice B Gottlieb
Department of Dermatology, Tufts New England Medical Center, Boston, MA 02111 1533, USA
J Dermatolog Treat 17:343-52. 2006..To assess the efficacy and tolerability of etanercept to treat psoriatic arthritis...
Folate supplementation during methotrexate therapy for patients with psoriasisBruce E Strober
Department of Dermatology, New York University School of Medicine, New York, New York, USA
J Am Acad Dermatol 53:652-9. 2005..After examining the available data from the literature and drawing from clinical experience, we advise folate supplementation for every patient who receives methotrexate...
Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximabBruce E Strober
Arch Dermatol 140:366. 2004
Etanercept does not effectively treat moderate to severe alopecia areata: an open-label studyBruce E Strober
The Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA
J Am Acad Dermatol 52:1082-4. 2005..Based on these results, etanercept appears to be ineffective in treating subjects with treatment-refractory, moderate to severe alopecia areata, alopecia totalis, or alopecia universalis...
The treatment of psoriasis with etanerceptBruce E Strober
Dermatopharmacology Unit, Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
Semin Cutan Med Surg 24:28-36. 2005..With appropriate patient selection and follow-up, etanercept therapy has a very good benefit-to-risk ratio and represents a convenient option for patients with moderate-to-severe psoriasis...
Etanercept for the treatment of psoriasis: combination therapy with other modalitiesBruce E Strober
Ronald O Perelman Department of Dermatology, New York University School of Medicine, USA
J Drugs Dermatol 3:270-2. 2004..Below are cases that demonstrate how etanercept can be combined with other medications in order to both maximize clinical efficacy and minimize potential risk...
Efalizumab-associated Guillain-Barre syndromeFrank Victor
Arch Dermatol 144:1396-7. 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball
Department of Dermatology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
J Am Acad Dermatol 58:1031-42. 2008....
Balancing immunity and immunosuppression: vaccinating patients receiving treatment with efalizumabShana Marmon
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA
J Invest Dermatol 128:2567-9. 2008..this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab...
Substantial alterations of the cutaneous bacterial biota in psoriatic lesionsZhan Gao
Department of Medicine, New York University School of Medicine, New York, New York, United States of America
PLoS ONE 3:e2719. 2008..001), whereas normal skin from the psoriatic patients showed intermediate levels (12.3+/-21.6%). We conclude that psoriasis is associated with substantial alteration in the composition and representation of the cutaneous bacterial biota...
Reconsidering liver biopsies during methotrexate therapyJeffery S Henning
J Am Acad Dermatol 56:893-4. 2007
The potential of interleukin 12 inhibition in the treatment of psoriasisDavid Rosmarin
Ronald O. Perelman Department of Dermatology, NYU School of Medicine, New York, NY, USA
J Drugs Dermatol 4:318-25. 2005..Some effective conventional psoriasis treatments alter IL-12 levels. Importantly, specific antibodies directed against IL-12 may prove useful against psoriasis but may also act by targeting IL-23 in addition to IL-12...
Alefacept in the treatment of psoriatic nail disease: a small case seriesChristopher T Cassetty
J Am Acad Dermatol 52:1101-2. 2005
Successful treatment of plaque psoriasis with self-administered subcutaneous alefaceptBruce E Strober
Arch Dermatol 141:1602. 2005
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group studyJames Leyden
Skin Study Center, Broomall, PA, USA
Arch Dermatol 142:605-12. 2006..To evaluate the efficacy of 3 maintenance regimens (topical tazarotene, oral minocycline hydrochloride, or both) in sustaining improvement in acne...
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitisDonald Belsito
University of Missouri, Kansas City, USA
J Am Acad Dermatol 55:40-6. 2006..CONCLUSIONS: Tacrolimus ointment 0.1% is well tolerated and significantly more effective than vehicle in treating chronically exposed, nickel-induced ACD...
Molecular analysis of fungal microbiota in samples from healthy human skin and psoriatic lesionsLuciana C Paulino
Department of Medicine, New York University School of Medicine, 550 First Ave, OBV-A 606, New York, NY 10016, USA
J Clin Microbiol 44:2933-41. 2006..These data indicate the predominance of Malassezia organisms in healthy human skin, host-specific variation, stability over time, and as yet, no consistent patterns differentiating psoriatic skin from healthy skin...
On multiple courses of alefaceptCraig L Leonardi
J Am Acad Dermatol 55:916-7. 2006
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser
Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA
Arch Dermatol 143:239-42. 2007....
The Köbner phenomenon and psoriatic arthritisRitu Saini
New York University School of Medicine, Ronald O. Perelman Department of Dermatology, New York, New York, USA
Cutis 72:405-6. 2003..Dermatologists should screen patients with psoriasis for accompanying PsA and consider recently traumatized joints that remain arthritic to be a component of this disease...
